Connect with us

Press Release

New Clinical Data Reveals MAIA Biotechnology’s THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

Published

on

–News Direct–

By Mangeet Kaur Bouns

Lung cancer remains the top cause of cancer-related deaths in the U.S., accounting for approximately 20% of all cancer fatalities. The American Cancer Society's projections for 2024 highlight the gravity of this issue, with an estimated 234,580 new lung cancer cases and about 125,070 deaths anticipated in the U.S. Of these, nearly 80% to 85% are non-small cell lung cancer (NSCLC) cases, highlighting the urgent need for effective treatments.

MAIA Biotechnology, Inc. (AMEX: MAIA), a clinical-stage biopharmaceutical company focused on developing telomere-targeting immunotherapies for cancer treatment, has unveiled promising new clinical data showcasing the efficacy of its lead product candidate, THIO, in treating NSCLC. This data emerges from a phase 2 clinical trial evaluating THIO in combination with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo), targeting patients with advanced NSCLC who have not responded to at least two standard-of-care therapies.

In the context of NSCLC, where traditional treatments often fall short, THIO's potential as a first-in-class telomere-targeting agent raises hope. Its ability to disrupt cancer cell telomeres and stimulate immune responses marks a significant advancement in the fight against this devastating disease.

MAIAs Lead Candidate: THIO

THIO is a groundbreaking telomere-targeting agent, currently undergoing phase 2 clinical trials aimed at treating NSCLC with telomerase-positive cancer cells. Telomerase, present in over 85% of human cancers, plays a crucial role in the immortality and proliferation of cancer cells. THIO integrates into telomeres within these cells, disrupting their structure and function leading to rapid tumor cell death.

By inducing telomerase-dependent DNA modification and damage, THIO triggers selective cancer cell death. This process accumulates telomeric damage in cytosolic micronuclei, which then activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. In in vivo cancer models, sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in significant and sustained tumor regression, fostering cancer-specific immune memory.

Key Findings From The Phase 2 THIO-101 Clinical Trial

The phase 2 THIO-101 trial primarily focuses on assessing the safety and tolerability of THIO both as an anticancer agent and as an immune system activator, alongside evaluating its clinical efficacy through overall response rate (ORR).

The trial results are noteworthy. The disease control rate (DCR) for THIO in combination with CPI was 85%, far exceeding the 25-35% DCR typically seen with chemotherapy in third-line treatments. Additionally, 65% of patients surpassed the 5.8-month overall survival (OS) threshold, and 85% exceeded the 2.5-month progression-free survival (PFS) threshold, demonstrating significant clinical benefits. The median survival follow-up time stood at 9.1 months for the cohort of 20 patients.

Optimal dose selection yielded even more impressive outcomes. Patients in third-line receiving 180mg of THIO exhibited a median PFS of 5.5 months, a 75% OS rate at six months and an ORR of 38%, compared to the standard 6-10% ORR for chemotherapy. Notably, 75% of these patients crossed the 5.8-month OS threshold and 88% surpassed the 2.5-month PFS threshold, with a median survival follow-up time of 9.1 months among the eight patients assessed.

Implications And Future Directions

Dr. Vlad Vitoc, chairman and CEO of MAIA, expressed enthusiasm about the trial outcomes, noting, "All exceptional measures of efficacy in our trial to date have exceeded our own expectations and outperformed standard-of-care treatments." He emphasized THIOs potential as a robust, safe and highly effective alternative for patients who have not benefited from chemotherapy and other treatments.

The THIO-101 trial, which completed enrollment ahead of schedule in February, reached its target of 41 patients for the 180 mg dose. This data, which indicates promising disease control and overall response rates, paves the way for further investigation and potential redefinition of cancer treatment protocols.

As THIO-101 data continues to demonstrate favorable disease control and response rates, with full efficacy data anticipated in the latter half of this year, MAIA Biotechnology stands poised to redefine cancer treatment. THIOs promise to transform the standard of care in oncology offers new hope to patients with advanced NSCLC, potentially establishing a new benchmark in cancer therapy.

Featured photo by CI Photos at Shutterstock.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/new-clinical-data-reveals-maia-biotechnologys-thio-achieves-high-efficacy-in-advanced-non-small-cell-lung-cancer-treatment-599831106

Benzinga

comtex tracking

COMTEX_453480766/2655/2024-06-07T08:20:02

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

BiFinance Lists EVOCARE-USDT and Launches Trading Competition with Exclusive Rewards

Published

on

BiFinance, a leading Web3 digital asset trading platform, has officially announced the listing of EVOCARE (EVOCARE) and the launch of a dedicated trading competition, offering users multiple participation opportunities and enhanced engagement.

EVOCARE Officially Listed on BiFinance

According to the official announcement, BiFinance has listed the EVOCARE USDT trading pair, with deposit and trading services opened on March 12, 2026.

EVOCARE represents an innovative Web3 healthcare initiative focused on building a digital therapy ecosystem. As The World Therapy Store, EvoCare aims to connect patients, therapists, and healthcare creators through a scalable and compliant infrastructure, integrating real-world medical services with blockchain technology and bringing real-world utility into the Web3 space.

The platform combines regulated healthcare services with Web3 utility infrastructure, creating a scalable global ecosystem for therapy, rehabilitation, and digital health services. EvoCare is designed to enable German-quality therapeutic care to be delivered anywhere in the world through a clinically supervised digital healthcare platform.

Official Website:

https://evocare.healthcare

The EVOCARE token serves as the core of the ecosystem, supporting:

Digital therapy service payments

Creator support mechanisms

Access to regulated healthcare solutions

By linking real healthcare demand with tokenized utility, EVOCARE creates a sustainable and value-driven ecosystem backed by real-world applications.

Trading Competition Now Live with Trading Competition Details

To celebrate the listing, BiFinance has launched the EVOCARE Trading Competition, allowing users to trade EVOCARE USDT and compete for benefits.

Participants can:

Trade EVOCARE USDT to climb leaderboard rankings

Receive benefits based on trading performance

Unlock additional advantages such as trading additional benefits

The competition is designed to encourage active participation while benefiting both new and experienced traders.

Expanding the RWA and Utility-Driven Ecosystem

The listing of EVOCARE reflects BiFinance’s continued commitment to supporting projects with real-world utility and strong growth potential. By bridging traditional sectors such as healthcare with blockchain infrastructure, BiFinance further strengthens its “virtual + real” ecosystem strategy.

Through ongoing listings, trading campaigns, and ecosystem collaboration, BiFinance aims to provide users with:

High-quality asset access

Enhanced trading opportunities

A more diversified and utility-driven Web3 experience

About BiFinance

BiFinance is a Web3 digital asset trading platform focused on the integration of Real-World Assets (RWA) and blockchain technology. The platform is committed to building a secure, compliant, and scalable financial ecosystem, connecting traditional finance with the decentralized world.

With a growing global presence and continuous innovation in both product and ecosystem design, BiFinance is accelerating the evolution of digital finance through its “Bi+Finance” model.

Media Contact

Organization: BiFinance

Contact Person: Ben

Website: https://www.bifinance.com

Email:
listing@BiFinance.com

Country:Canada

Release id:42777

The post BiFinance Lists EVOCARE-USDT and Launches Trading Competition with Exclusive Rewards appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Advanced Strapless Goalkeeper Gloves Officially Released, Available at Just Keepers

Published

on

Hinckley, Leicestershire, United Kingdom, 19th Mar 2026 – Just Keepers has added advanced strapless goalkeeper gloves to its selection, reflecting growing interest in strap-free designs within the goalkeeping community.

The Goalkeeper gloves feature a slip-on construction, removing the need for a traditional wrist strap and offering a clean, streamlined fit. This design approach aligns with the preferences of goalkeepers seeking simplicity and a more natural feel during play.

With a reduced structure around the wrist, the gloves are suited for both training and match environments, supporting comfort and ease of movement on the pitch.

Strapless gloves are becoming an increasingly talked-about option among goalkeepers. Their inclusion reflects the shift towards more simplified designs in modern goalkeeping gear.

The addition highlights ongoing changes in goalkeeper equipment, as players continue to explore new styles and fits that suit their individual preferences.

For more information
https://www.just-keepers.com/goalkeeper-gloves/goalie-gloves/reusch-gk-gloves/

About Just Keepers Ltd

Just Keepers is a dedicated retailer specialising exclusively in goalkeeping equipment, offering a curated selection tailored to the specific needs of the position. Its range covers goalkeeper gloves, technical clothing, and essential accessories suited for both training sessions and competitive matches. Catering to players at every level, from beginners to professionals, the company focuses on purpose-built gear, durability, and consistent performance across its lineup.

Media Contact

Organization: Just Keepers Ltd

Contact Person: Just Keepers Ltd

Website: https://www.just-keepers.com/

Email: Send Email

City: Hinckley, Leicestershire

Country:United Kingdom

Release id:42820

The post Advanced Strapless Goalkeeper Gloves Officially Released, Available at Just Keepers appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Macmillan Lawyers and Advisors Supports Brisbane Businesses with Strategic Legal Advisory Services

Published

on

Australia, 19th Mar 2026 – Macmillan Lawyers and Advisors, a respected Brisbane-based commercial law firm, has strengthened its strategic legal advisory services to support businesses across Brisbane navigating complex commercial and regulatory environments. The firm provides guidance to organisations at various stages of development, including business establishment, dispute resolution, and financial restructuring.

Operating from Level 38, 71 Eagle Street in Brisbane City, Macmillan Lawyers and Advisors works with businesses ranging from emerging enterprises to established companies. Legal advice is designed to assist organisations managing contractual obligations, regulatory compliance requirements, and operational challenges.

Across Australia, businesses continue to face evolving regulations, economic pressures, and changing market conditions. These developments have increased demand for legal advisory services that help organisations identify risks and address complex legal matters early.

Macmillan Lawyers and Advisors provides services across several areas of commercial law, including contract law, commercial disputes, intellectual property protection, bankruptcy and insolvency matters, liquidation processes, and turnaround strategies. Legal support focuses on helping businesses understand their legal responsibilities while developing practical approaches to commercial challenges.

Kyle Macmillan, Principal of Macmillan Lawyers and Advisors, said strategic legal guidance plays an important role for businesses operating in a changing commercial environment.

“Businesses across Brisbane are navigating an environment that requires careful legal and strategic planning,” said Macmillan. “Access to experienced legal advisory services assists organisations in addressing disputes, contractual obligations, and financial restructuring matters in a structured and informed manner.”

The firm provides legal support throughout different stages of the corporate lifecycle. Early-stage assistance includes advice on company establishment, governance structures, shareholder agreements, and intellectual property protection. For established organisations, services often involve dispute resolution, contract negotiation, and regulatory compliance guidance.

Macmillan Lawyers and Advisors also advises businesses experiencing financial difficulty or operational restructuring. Legal support in insolvency, bankruptcy, and turnaround planning helps organisations understand available legal options and obligations during periods of financial stress.

Industry professionals note that early legal guidance can assist businesses in managing disputes and addressing potential financial challenges before problems escalate. Strategic legal planning is increasingly viewed as an important component of responsible corporate governance and long-term stability.

Macmillan noted that ongoing changes within regulatory environments highlight the importance of consistent legal insight.

“Changes within regulatory environments and market conditions highlight the importance of ongoing legal insight for businesses,” Macmillan said. “Strategic advisory services will continue to support organisations as they adapt to future challenges while maintaining compliance and operational resilience.”

For media enquiries, Macmillan Lawyers and Advisors, a business lawyer Brisbane firm providing commercial legal services to organisations across Queensland, can be contacted at Level 38, 71 Eagle Street, Brisbane City QLD 4000. Enquiries may be directed by phone on (07) 3518 8030 or via email at admin@macmillan.law.

Media Contact

Organization: Macmillan Lawyers and Advisors

Contact Person: Kyle Macmillan

Website: https://macmillan.law/

Email: Send Email

Contact Number: +61735188030

Address:Level 38/71 Eagle St

Address 2: Brisbane City QLD 4000

Country:Australia

Release id:42813

The post Macmillan Lawyers and Advisors Supports Brisbane Businesses with Strategic Legal Advisory Services appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST